ChemoCentryx Appoints Tausif (‘Tosh’) Butt as Executive Vice President and Chief Operating Officer
February 24 2021 - 8:30AM
ChemoCentryx, Inc., (Nasdaq: CCXI), today announced the appointment
of Tausif (‘Tosh’) Butt as Executive Vice President and Chief
Operating Officer, reporting directly to President and Chief
Executive Officer Thomas J. Schall, Ph.D. In this new capacity at
ChemoCentryx, Tosh Butt will oversee many of the Company’s
operational functions, and further strengthen the commercial
infrastructure that ChemoCentryx has developed in anticipation of
the launch of avacopan for the treatment of ANCA-associated
vasculitis. A New Drug Application for avacopan is currently under
review by the U.S. Food and Drug Administration, with a PDUFA goal
date of July 7, 2021.
Prior to joining ChemoCentryx, Tosh Butt served as the Senior
Vice President of Latin America for AstraZeneca, where he led a
team of more than 2,000 people, including five country presidents,
while delivering approximately $1B in net sales across the
company’s full portfolio including oncology. Serving in leadership
roles at Astra Zeneca for more than six years -- in marketing,
sales, and market access -- across the company’s primary care,
biologics and vaccines, and oncology business lines, Tosh Butt
launched products in both primary and specialty care, including the
company’s first biologic. Prior to this, he held several marketing
and sales leadership roles in the United States, United Kingdom and
France with GlaxoSmithKline and Sanofi.
“Today we add strength to strength with the addition of Tosh to
our ChemoCentryx Community, to enhance the solid infrastructure we
have in place,” said Thomas J. Schall, Ph.D., President and Chief
Executive Officer of ChemoCentryx. “In his 20-plus years at leading
pharmaceutical organizations, Tosh has expertly run complex
operations, overseeing the roles of literally thousands of
biopharmaceutical professionals. Moreover, Tosh has the added
benefit of being deeply steeped in the commercial side of our
industry. This expanded dimension of experience perfectly
complements the already remarkable, robust foundation that has been
established by our talented ChemoCentryx commercial team.”
“I’m thrilled to be joining the ChemoCentryx team at this
exciting juncture, with the company’s first New Drug Application
under FDA review, and results recently announced in two other
indications, moving the company closer in its mission to bring
better medicines to the patients who need them most,” added Mr.
Butt. “As the company approaches potential commercialization this
year, I believe my experience and depth of knowledge in sales,
marketing and product management will aid in the company’s
successful execution now and well into the future.”
Beginning his career as a retail pharmacist, having received a
degree in Pharmacy from the University of Brighton in the UK, Tosh
Butt also holds an MSc in Management from Imperial College,
University of London.
About ChemoCentryxChemoCentryx is a
biopharmaceutical company developing new medications for
inflammatory and autoimmune diseases and cancer. ChemoCentryx
targets the chemokine and chemoattractant systems to discover,
develop and commercialize orally-administered therapies.
ChemoCentryx’s lead drug candidate, avacopan (CCX168), successfully
completed a pivotal Phase III trial in ANCA-associated vasculitis
and a New Drug Application is under review by the U.S. Food and
Drug Administration. Avacopan is also in late stage clinical
development for the treatment of severe Hidradenitis Suppurativa
and C3 glomerulopathy (C3G).ChemoCentryx also has early stage drug
candidates that target chemoattractant receptors in other
inflammatory and autoimmune diseases and in cancer.
Forward-Looking StatementsChemoCentryx cautions
that statements included in this press release that are not a
description of historical facts are forward-looking statements.
Words such as "may," "could," "will," "would," "should," "expect,"
"plan," "anticipate," "believe," "estimate," "intend," "predict,"
"seek," "contemplate," "potential," "continue" or "project" or the
negative of these terms or other comparable terminology are
intended to identify forward-looking statements. These statements
include the Company's statements regarding the timing of
anticipated PDUFA date for the avacopan NDA for the treatment of
ANCA-associated vasculitis, the achievement of anticipated goals
and milestones, whether avacopan will be approved by the FDA or EMA
for the treatment of ANCA-associated vasculitis, whether avacopan
will be an effective treatment in other indications such as C3G or
severe HS, and whether the Company's drug candidates will be shown
to be effective in ongoing or future clinical trials. The inclusion
of forward-looking statements should not be regarded as a
representation by ChemoCentryx that any of its plans will be
achieved. Actual results may differ from those set forth in this
release due to the risks and uncertainties inherent in the
ChemoCentryx business and other risks described in the Company's
filings with the Securities and Exchange Commission ("SEC").
Investors are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof,
and ChemoCentryx undertakes no obligation to revise or update this
news release to reflect events or circumstances after the date
hereof. Further information regarding these and other risks is
included under the heading "Risk Factors" in ChemoCentryx's
periodic reports filed with the SEC, including ChemoCentryx's
Annual Report on Form 10-K filed with the SEC on March 10, 2020 and
its other reports which are available from the SEC's website
(www.sec.gov) and on ChemoCentryx's website (www.chemocentryx.com)
under the heading "Investors." All forward-looking statements are
qualified in their entirety by this cautionary statement. This
caution is made under the safe harbor provisions of Section 21E of
the Private Securities Litigation Reform Act of 1995.
Contacts:Susan M. KanayaExecutive Vice
President,Chief Financial and Administrative
Officerinvestor@chemocentryx.com
Media:Stephanie
Tomei408.234.1279media@chemocentryx.com
Investors:Burns McClellan, Inc.Lee
Roth212.213.0006lroth@burnsmc.com
ChemoCentryx (NASDAQ:CCXI)
Historical Stock Chart
From Aug 2024 to Sep 2024
ChemoCentryx (NASDAQ:CCXI)
Historical Stock Chart
From Sep 2023 to Sep 2024